Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have earned a consensus rating of “Hold” from the eight research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.33.

A number of research firms have recently issued reports on LXRX. Wedbush reissued an “outperform” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, October 5th. Needham & Company LLC reissued a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, BidaskClub lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 10th.

Lexicon Pharmaceuticals (NASDAQ:LXRX) traded up $0.18 during midday trading on Friday, hitting $9.75. 833,396 shares of the stock were exchanged, compared to its average volume of 811,913. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09. Lexicon Pharmaceuticals has a 1-year low of $8.07 and a 1-year high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.07. The business had revenue of $26.94 million during the quarter, compared to analyst estimates of $27.97 million. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The firm’s revenue was down 2.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.35) earnings per share. sell-side analysts predict that Lexicon Pharmaceuticals will post -1.45 EPS for the current fiscal year.

In other Lexicon Pharmaceuticals news, Director Public Equities L.P. Invus acquired 145,680 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average price of $9.74 per share, with a total value of $1,418,923.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Lonnel Coats acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were acquired at an average cost of $9.91 per share, for a total transaction of $99,100.00. Following the transaction, the chief executive officer now owns 42,985 shares of the company’s stock, valued at approximately $425,981.35. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 945,353 shares of company stock worth $9,304,953. Insiders own 5.77% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. grew its holdings in Lexicon Pharmaceuticals by 0.3% during the first quarter. Principal Financial Group Inc. now owns 22,684 shares of the biopharmaceutical company’s stock valued at $325,000 after purchasing an additional 70 shares during the last quarter. Vanguard Group Inc. grew its holdings in Lexicon Pharmaceuticals by 16.3% during the first quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock valued at $59,773,000 after purchasing an additional 585,222 shares during the last quarter. Geode Capital Management LLC grew its holdings in Lexicon Pharmaceuticals by 1.0% during the first quarter. Geode Capital Management LLC now owns 433,420 shares of the biopharmaceutical company’s stock valued at $6,215,000 after purchasing an additional 4,141 shares during the last quarter. Morgan Stanley grew its holdings in Lexicon Pharmaceuticals by 22.7% during the first quarter. Morgan Stanley now owns 174,765 shares of the biopharmaceutical company’s stock valued at $2,505,000 after purchasing an additional 32,276 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Lexicon Pharmaceuticals during the first quarter valued at approximately $3,750,000.

TRADEMARK VIOLATION WARNING: “Analysts Set Lexicon Pharmaceuticals, Inc. (LXRX) Price Target at $25.33” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/analysts-set-lexicon-pharmaceuticals-inc-lxrx-price-target-at-25-33/1720562.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.